Universal access to affordable essential medicines remains an unmet goal, and while the World Health Organization has been attempting to address this problem through prequalification of drugs like insulin to help ensure access for patients in low-resource areas, costs for many products remain prohibitive.
Universal access to affordable essential medicines remains an unmet goal, and while the World Health Organization (WHO) has been attempting to address this problem through prequalification of drugs like insulin to help ensure access for patients in low-resource areas, costs for many products remain prohibitive.
Manufacturing costs are often cited as one reason for steep prices, particularly for drugs like biologics. However, in a recent paper, a group of authors sought to develop an algorithm to estimate the cost of injectable medicines on the WHO’s List of Essential Medicines (EML) and to use that algorithm to estimate the prices that would be expected given an average profit margin.
Injectable drugs on the WHO list include products like anti—tumor necrosis factor therapies and their biosimilars, as well as anticancer biologics and their biosimilars.
The investigators derived data on the cost of active pharmaceutical ingredients (APIs) exported from India using an online database of customs declarations in order to design their algorithm to estimate cost-based drug pricing. In total, 96 drugs on the list had API data available.
They also included costs to convert APIs into finished pharmaceutical products using the eMIT database, and they collected prices on drugs from databases in the United Kingdom, South Africa, and India.
They found that prices based on cost plus an average profit margin would range from a low of $0.24 for salbutamol to a high of $449 for a 500-mg vial of rituximab. However, a majority of injectables had prices significantly higher than the estimated cost-based prices in the United Kingdom and South Africa. In total, 77% of medicines had prices over the estimated cost-based price in England, as did 62% of medicines in South Africa. In India, 85% of medicines had prices below the estimated cost-based price.
The products that had the highest ratios of lowest current price versus the estimated cost-based price included filgrastim in the United Kingdom (radio, 112.6) and insulin injection in India (ratio, 2.7).
“Most injectable medicines on the EML can be manufactured at very low cost,” write the authors. Although they note that the wide range of medicines included in the analysis makes it difficult to generalize about the appropriateness of pricing, and that the analysis was unable to detect anticompetitive strategies that may raise prices, drugs with prices significantly higher than their cost to manufacture may represent a substantial burden on healthcare systems.
Estimating the cost to produce these drugs, the authors say, could help governments to develop drug pricing mechanisms to reduce some of this burden.
Reference
Gotham D, Barber MJ, Hill AM. Estimation of cost-based prices for injectable medicines in the WHO essential medicines list. BMJ Open. 2019;9:e027780. doi: 10.1136/bmjopen-2018-027780.
Julie Reed: Why 2024 Is Important for Biosimilars
April 17th 2024Julie Reed, executive director of the Biosimilars Forum, showcases how the biosimilar industry is expected to develop throughout 2024, including major policy changes and hope for continued improvement in market share for adalimumab biosimilars.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
BioRationality: Removing the Misconceptions Surrounding Interchangeability
April 15th 2024Sarfaraz K. Niazi, PhD, outlines the current state of interchangeable biosimilars in the US and policy changes needed to clear up misconceptions surrounding the meaning behind interchangeability designations.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
Biosimilars Council: PBM Rebate Schemes Cost Americans, Payers $6 Billion
April 10th 2024A report from the Biosimilars Council evaluating IQVIA data found that rebate schemes orchestrated by pharmacy benefit managers (PBMs) are costing US patients and payers billions of dollars by suppressing biosimilar adoption.
Rising Biosimilar Adoption for an Italian Payer Will Benefit National Health Care System, Patients
April 9th 2024Data from 2021 and 2022 indicates increasing biosimilar use in an Italian health care company, with potential for full adoption in the future, benefiting both the National Health System and citizens through efficient and sustainable health care policies.